Crystalloid Versus Colloid Rapid Co-load for Cesarean Delivery Under Spinal Anesthesia

Sponsor
Seoul National University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03729076
Collaborator
(none)
100
1
2
13.9
7.2

Study Details

Study Description

Brief Summary

The study aims to compare crystalloid co-loading and colloid co-loading in parturients receiving prophylactic phenylephrine infusion during cesarean delivery in terms of the incidence of hypotension.

Condition or Disease Intervention/Treatment Phase
  • Other: Crystalloid
  • Other: Colloid
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Crystalloid Versus Colloid Rapid Co-load in Parturients Receiving Prophylactic Phenylephrine Infusion During Cesarean Delivery Under Spinal Anesthesia
Actual Study Start Date :
Nov 16, 2018
Actual Primary Completion Date :
Jan 8, 2020
Actual Study Completion Date :
Jan 12, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Crystalloid

Patients will receive rapid co-load of plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia.

Other: Crystalloid
Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.

Active Comparator: Colloid

Patients will receive rapid co-load of 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia.

Other: Colloid
Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.

Outcome Measures

Primary Outcome Measures

  1. Incidence of maternal hypotension [during the time period from induction of spinal anesthesia until delivery]

    defined as: Systolic Blood Pressure (SBP) < 80% of baseline SBP

Secondary Outcome Measures

  1. incidence of severe hypotension [during the time period from induction of spinal anesthesia until delivery]

    defined as: Systolic Blood Pressure (SBP) < 70% of baseline SBP

  2. incidence of symptomatic hypotension [during the time period from induction of spinal anesthesia until delivery]

    defined as: hypotension plus nausea and/or vomiting and/or dizziness and/or breathlessness

  3. incidence of bradycardia [during the time period from induction of spinal anesthesia until delivery]

    Heart Rate (HR) <50 bpm

  4. incidence of Hypertension [during the time period from induction of spinal anesthesia until delivery]

    Systolic Blood Pressure (SBP)> 120% of baseline SBP

  5. Minimum recorded Systolic Blood Pressure (Minimum SBP) [during the time period from induction of spinal anesthesia until delivery]

    The lowest recorded SBP during the time period from induction of spinal anesthesia until delivery

  6. Minimum recorded Heart Rate (Minimum HR) [during the time period from induction of spinal anesthesia until delivery]

    The lowest recorded HR during the time period from induction of spinal anesthesia until delivery

  7. Cumulative duration of hypotension [during the time period from induction of spinal anesthesia until delivery]

    duration of hypotension, minutes

  8. Onset time of hypotension [during the time period from induction of spinal anesthesia until delivery]

    Time from the induction of spinal anesthesia until the first event of hypotension occur

  9. Total phenylephrine use [during the time period from induction of spinal anesthesia until delivery]

    Cumulative dose of phenylephrine administered via continuous infusion, mcg

  10. Rescue phenylephrine use [during the time period from induction of spinal anesthesia until delivery]

    number of patients who require the rescue use of phenylephrine

  11. Rescue ephedrine use [during the time period from induction of spinal anesthesia until delivery]

    number of patients who require the rescue use of ephedrine

  12. Atropine use [during the time period from induction of spinal anesthesia until delivery]

    number of patients who require the rescue use of atropine

  13. Incidence of nausea, vomiting [during the time period from induction of spinal anesthesia until delivery]

    The incidence of nausea, vomiting

  14. Incidence of dizziness, breathlessness [during the time period from induction of spinal anesthesia until delivery]

    The incidence of dizziness, breathlessness

  15. Cutaneous stellate ganglion sympathetic activity [during the time period from induction of spinal anesthesia until delivery]

    noninvasive recording of skin sympathetic nerve activity (SKNA) using conventional ECG electrodes

  16. Apgar Score, 1 min, 5 min (fetal outcome) [1 min, 5 min after delivery]

    Apgar Score of delivered baby. The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. The five criteria are the Appearance, Pulse, Grimace, Activity, and Respiration. Each is scored on a scale of 0 to 2, with 2 being the best score. The test is done at 1 and 5 minutes after birth.

  17. Umbilical arterial pH [immediately after delivery]

    pH of Umbilical Arterial blood gas analysis (ABGA) (fetal outcome)

  18. Umbilical arterial base excess [immediately after delivery]

    base excess of Umbilical ABGA (fetal outcome), mmol/L

  19. Umbilical arterial partial oxygen pressure (PO2) [immediately after delivery]

    partial oxygen pressure of Umbilical ABGA (fetal outcome), mmHg

  20. Umbilical arterial carbon dioxide partial pressure (PCO2) [immediately after delivery]

    carbon dioxide partial pressure of Umbilical ABGA (fetal outcome), mmHg

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Healthy, full-term parturients who scheduled to undergo elective cesarean delivery under spinal anesthesia.
Exclusion Criteria:
  • multiple pregnancy

  • gestational age < 36 weeks

  • preexisting or pregnancy-induced hypertension

  • Morbid cardiovascular impairments

  • Cerebrovascular disease

⑥ Known fetal anomaly

⑦ Contraindications to spinal anesthesia

⑧ Any sign of onset of labor

⑨ Body weight < 45 kg or body weight > 90 kg

⑩ Height < 145cm or height > 180cm

Contacts and Locations

Locations

Site City State Country Postal Code
1 Seoul National University Hospital Seoul Korea, Republic of

Sponsors and Collaborators

  • Seoul National University Hospital

Investigators

  • Principal Investigator: Jin-Tae Kim, MD, PhD, Seoul National University Hospital, Seoul National University College of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jin-Tae Kim, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT03729076
Other Study ID Numbers:
  • H-1807-152-961
First Posted:
Nov 2, 2018
Last Update Posted:
Feb 5, 2020
Last Verified:
Jan 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 5, 2020